mardi 10 décembre 2013

25 Ways to Get Back on Track

At one time or another you had some serious fire and couldn’t wait to start living healthier. The time will come when the “newness” wears off and you’ll probably lose quite a bit of the motivation you started with. Let me first just say that nobody is perfect and most of us have gotten back on track several times over. To some, getting back on track happens after a weekend full of crap eating and for others it might mean getting back on track after a long hiatus. Whether it’s been 2 days or 2 years, it’s never too late to get back on track!

One of my challengers this month inspired me to write up this post and in honor of our wedding anniversary today (July 25th) I present to you:

25 ways to get back on track

1. Track all of your food intake today. No matter what you eat, you’ll learn from it.

2. Try a quick workout. Take a 5-minute walk, it’s better than nothing!

3. Mix up your playlist. Whether you workout with DVDs or in the gym, change your track list to help you get pumped up again.

4. Drink water. Many people forget to track their drinks when keeping a food diary – drinks count too! Whether it’s coffee, tea, alcoholic, juice, etc…try replacing one of those drinks each day with a glass of cold ice water.

5. Bring your workouts outside for a change of scenery.

6. Call someone you care about and tell them your short term goal. This can help hold you accountable.

7. Track your workouts. You can do this using a notebook or online using things like MyFitnessPal or TeamBeachbody (they’re all FREE!). Seeing those workouts get done will help motivate you to keep going.

8. Try a new recipe. This always works for me! (AllRecipes.com and Pinterest.com are great for this)

9. Do a monthly challenge. There are tons of these available! It could be my 30-90 day challenge or even something as simple as a 30-day squat or plank challenge.

10. Reward yourself. If you’re just starting out, reward yourself after an entire week with no missed workouts. (good ideas include a sports bra, new workout songs or new gym shorts)

11. Start small. You don’t have to hit the ground running. This could mean one small change in your diet (for example – drinking pop every 2 days instead of every day; this IS progress)

12. Sign up for a fun run. I’ve done several of these so far and I remember being scared to death prior to my very first run. Signing up for your first 5K will motivate you to keep working so that you’re able to successfully complete that run. And I promise they aren’t that hard and all the other runners/walkers are very supportive!

13. Start NOW. Don’t wait until tomorrow…or the dreaded Monday.

14. Plan your meals. I cannot keep my diet real clean if I don’t plan my meals. Planning makes all the difference for me and it doesn’t have to take a lot of time.

15. Recommit. Think about *WHY* you want to be healthier. WRITE IT DOWN.

16. Ignore sabotagers. I don’t know if that’s a word but it makes sense to me! You know the people I’m talking about…the ones who give you crap because they’ve noticed you’re eating healthier these days. The ones who polk fun because you avoid the morning donuts at work. The ones who make smart-ass comments about your lifestyle. Ugh!! Let me just say that the only reason people do that is because it makes them uncomfortable for their own sake. It’s not about YOU, it’s about THEM.

17. Try a 7-day food challenge. This could be eating clean for 7 days or trying a pale0 or gluten-free challenge for 7 days. I did a 30-day paleo challenge and it helped me tremendously even though I don’t stick to it 100% of the time right now. It made me feel amazing!

18. Treat yourself to a new cookbook with healthy recipes! Some good ones are The Eat Clean Diet or The Hungry Girl cookbooks.

19. Healthy living cannot stop. Once you realize this, it’ll make things easier. When you meet your “goal weight” or “ideal body” you can’t quit. To reap the benefits of healthy living you’ve got to commit for LIFE! Doesn’t always mean things will be perfect…and you will have struggles, but have the perseverance to NOT GIVE UP. EVER. If you do? Come back to this post to get started again. :)

20. Ask your friends/family members for help. Don’t try to do everything on your own. Ask your spouse, significant other, parents, cousins, aunts, uncles, etc., if they will commit WITH you. It’s a lot easier if the people you live with (or spend a lot of your time with) are on board.

21. Read personal development books. These will help you change your mindset and your mindset is SO important when it comes to all aspects of your life. For example, right now I’m reading “The Purpose Driven Life”. They are small chapters so I just spend a few minutes each day reading one. You might wonder how on earth this will help you get back on track but try it for 7 days and let me know how you’re feeling. It’s a life-changer!

22. Turn negative thoughts into positive ones. Easier said than done, I KNOW. But the effort is worth it and can make ALL the difference! I’ve written about this several times on the blog here, here and here.

23. Forgive yourself.

24. Start a blog! It will help hold yourself accountable and makes it easy to share your journey with others! That’s why this blog exists and turned FIVE this year.

25. Realize that you DESERVE the body YOU DESIRE – whatever that means for you! This blog isn’t about perfection…I laugh in the face of perfection. Hahahahahaha. I got dents and stretch marks and I don’t always get excited about workouts…but I do know that I deserve what I have and what I’m ultimately working towards!

*****

Q. What helps YOU stay on track? Share it below – it just may help somebody else too!

Urethritis – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

All sexual partners who came in contact with the patient within 60 days should be evaluated, tested, and treated for both gonorrhea and chlamydia.

lundi 9 décembre 2013

Urolithiasis – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

Your Are Here: Health tips ? Diseases & Conditions ? Alphabetical ? U ? Urolithiasis – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

Tuberculosis, Latent – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

BCG vaccine, live-attenuated M. bovis: Used more commonly in developing countries to prevent complications of TB, especially in children

Western Herbal Medicine – History, How Herbs Work, Safety and Efficacy

MEDICINALLY ACTIVE PLANT CHEMICALS

Plants do not have an immune system like ours to protect them from attack. Instead they use chemicals to fight bacteria, fungi and insects. Because these chemicals are biologically active, some also have medicinal properties.

Antimicrobials prevent the bulb rotting in wet soilGinsenosides

(triterpene saponins)

Protection against fungal diseasesThe tannins coagulate protein, so are an effective insect deterrentThe coagulating properties of bark tannins can be used for diarrhoeaEchinacea

Echinacea purpurea, pallida, augustiflora

Complex mix of alkylamides, caffeic acid derivatives, palyalkynes and polysaccharides

Antifungal compoundsare a defence against fungal diseaseStimulates the immune system. Used for upper respiratory tract infectionsSt John’s wort

Hypericum perforatum

Hypericin and pseudohypericin

 (naphthodianthrones)

Defence against insects that try to eat the plantBlocks neurotransmitter re-uptake. Used for depressionDeter or prevent insect or slug attackProvide its antispasmodic action. Used for indigestion

Since the 18th century scientists have been isolating the active constituents in plants. Research has given rise to some of the world’s most powerful drugs. Even today, modern medicine relies heavily on plant-derived drugs.

Not only have some of the more long-standing drugs such as digoxin, opiates and aspirin originated from plants, but many of the newer high-tech drugs such as the cancer drug vincristine and other cytotoxics (chemicals that kill cells) are also chemicals derived from plants.

Herbal medicines, however, are different from plant- derived drugs in that they consist of many chemical components. The mixture works in concert, making active constituents more easily available to the body, or buffering otherwise harmful ingredients. This means that the total therapeutic effect of the whole plant is considerably more than the sum of its chemical parts, since the active constituents’ effects will be modified by other substances. What’s more, the complex arrays of chemicals found in even the simplest plant medicines can trigger a cascade of biochemical processes in the living body. The way herbal medicines work is unlike the linear cause and effect of a single chemical (drug) acting on a single receptor system – a mechanism that pharmacologists are familiar with.

Understanding how plant medicines work calls for a leap into notions of “complexity” and “chaos” which are more familiar to physicists, than to biochemists or pharmacologists.

The consequences of using the whole plant rather than an isolated component are easily illustrated by clinical studies of garlic (Allium sativum). Recent research has shown that because garlic can lower blood pressure and cholesterol, it may be useful to people with coronary artery disease. Yet despite their best efforts, researchers have so far failed to identify which of garlic’s many chemical constituents are responsible for these medicinal virtues. Though formerly attributed to allicin, a compound found in garlic oil, it has recently become clear that the cholesterol- lowering effect of garlic results from a concerted action of several chemicals, not all of which are in the oil itself.

Research into St John’s wort (Hypericum perforatum) illustrates the same point. Trials have demonstrated that this ancient remedy is very effective in a wide range of depressive disorders, including seasonal affective disorder. It is as effective as modern antidepressant drugs in treating mild to moderate depression, but provokes virtually none of their side-effects. Researchers, however, cannot as yet assign the plant’s antidepressant effects to specific chemical components. Another group of chemicals with huge medicinal potential that is not yet well understood are flavonoids. These are chemical compounds that give many flowers, fruits and vegetables their colour. They display an amazingly broad range of medicinal activity: improving capillary fragility and circulation, protecting the liver and preventing heart attacks and strokes. Some are antioxidant or anti-inflammatory and antiviral, while others have demonstrable anticancer properties.

The rapidly expanding body of research into plant pharmacology is challenging the very basis of drug-based medicine. The realisation that many apparently minor chemical constituents, until recently overlooked, have significant medicinal properties has come as a revelation.

Herbal practice relies on the gentle and supportive nature of the remedies it uses. In contrast to conventional medicine, herbal practitioners focus on the person rather than the disease label. The herbal practitioner will explore the background of the illness taking a comprehensive case history, in which family and personal life are carefully evaluated. Questions cover lifestyle, exercise and diet, as well as how the patient feels about his or her circumstances (job, relationships, aspirations and anxieties). Then the practitioner is likely to perform a physical examination and may order clinical tests. All this information is used to assess the vitality of the patient, and establish which systems are sluggish and which are overworked. The practitioner will prescribe a mixture of herbs accordingly.

The herbal prescription is not a simple matter of using herbs in the place of drugs to treat a particular condition. Drugs are standardised, while herbal treatment rarely is. Each prescription is unique to the patient, matching the needs of that person, supporting ailing systems and/or reducing over-activity when it is apparent.

In practice, herbs are not usually used as “simples” (i.e. given singly), but are combined for extra effect to suit the individual. St John’s wort, for example, though marketed as a remedy to treat mild to moderate depression, is commonly combined with other herbs. When St John’s wort is combined with lemon balm (Melissa officinalis), it is used to treat anxiety and depression; with wild oat (Avena fatua) and/or ginseng (Panax ginseng), it is given for exhaustion; with valerian (Valeriana officinalis), it is a treatment for bipolar mood disorder.

Herbs often confer a wide spectrum of benefits. For example, lemon balm can be used for anxiety and insomnia, but it is also traditionally used for calming a nervous stomach and bowel. Recently it has been found to have a significant antiviral effect and may also help in the treatment of hyperthyroidism. Herbal remedies can support and stimulate the body’s healing response. The herbalist and the patient are partners in this aim, working together towards the common goal of restoring health.

It is clear that “natural” does not always equal “safe”, and that herbal medicines, like conventional medicines, can cause adverse effects. Such adverse events may also be due to contaminants present in herbs, such as heavy metals or aflatoxins, or even because of misidentification of a herb. There is a possibility of herb-drug interactions too (see below), Therefore herbal practitioners must be very well trained and know exactly what other medicines their patients are taking.

Safety concerns should be set in context. The European Herbal Practitioners’Association estimates that in 2003 there were over a million herbal consultations in the UK. According to a BBC poll (August 1999), herbal medicines are the most popular form of self-care.

It would appear that the incidence of herbal adverse effects is rather low. A five-year study into the occurrence of adverse events involving traditional herbal medicines and food supplements was undertaken by the UK National Poisons Unit. Of the 1,297 enquiries received, a medicine was implicated as a probable cause of the adverse events in only 38 cases. The Ministry of Agriculture, Fisheries and Food commented: “The findings overall are reassuring as they do not indicate any significant health problems associated with most types of traditional remedies and dietary supplements.” However, there have been a number of important concerns regarding the safety of herbal medicines in the past two decades. Using toxic Aristolochia species instead of safer herbs in some traditional Chinese medicines resulted in cases of serious kidney poisoning and cancer in Europe, China, Japan and the US.

Volatile oils such as menthol and thymol have a pungent aromatic aroma and a range of actions because they penetrate easily through the body’s tissues. Their molecules can even affect the brain directly through the nose. Herbalists have long known that the aroma of crushed mint (Mentha) or rosemary (Rosmarinus officinalis) can increase alertness and improve concentration. Internally, these oils are carminative, relaxing an over-contracted intestinal tract. They also stimulate the heart and lungs, improving circulation and deepening breathing. These oils are excreted through the lungs, kidneys and skin, so they act as expectorants and mild diuretics, causing therapeutic sweating. The traditional germicidal properties of many volatile oils, such as from thyme (Thymus), tea tree (Melaleuca alternifolia) and garlic (Allium sativum), are effective to a surprising degree. Garlic has recently been shown to combat the common cold and the hospital superbug MRSA.

Professor Ernst, Chair of Complementary Medicine at the University of Exeter, has recently downplayed the threat of adverse effects from herbal medicines. In an editorial in the British Medical Journal he comments that “Even though herbal medicines are not devoid of risk, they could still be safer than synthetic drugs. Between 1968 and 1997, the World Health Organization’s monitoring centre collected 8985 reports of adverse events associated with herbal medicines from 55 countries. Although this number may seem impressively high, it amounts to only a tiny fraction of adverse events associated with conventional drugs held in the same database. However, the relative paucity could also be due to a relatively higher level of underreporting

At present, the relative safety of herbal medicines is undefinable, but many of the existing data indicate that adverse events, particularly serious ones, occur less often than with prescription drugs.”

Only a tiny fraction of herbal medicines have been fully researched. In some cases, this has led to doctors doubting their efficacy. However, in the same editorial, Professor Ernst dispels the myth that herbal remedies are ineffective and lack credibility because they have not been researched. He writes, “The efficacy of herbal medicines has been tested in hundreds of clinical trials, and it is wrong to say that they are all of inferior methodological quality. But this volume of data is still small considering the multitude of herbal medicines – worldwide several thousand different plants are being used for medicinal purposes.”

Relatively few rigorous clinical trials have been conducted on herbal therapies mainly because, compared with the pharmaceutical sector, the herbal industry can rarely afford the considerable expense of a clinical trial.

Not being able to patent plant medicines and recoup the costs as drug companies are able to do, puts the herbal industry at a very real disadvantage. However, most of those clinical trials that have been conducted have shown that herbal medicines do work. In a recent overview of 23 systematic reviews (which are comparative and critical analyses of many research studies) of rigorous trials of herbal medicines, 11 came to a positive conclusion, nine yielded promising but not convincing results, and only three were actually negative.

In most developed countries, herbal medicines are subject to increasing regulation. Most major professional herbal associations are now reporting any side-effects so information may be shared among professionals. Proposed new European Union and UK medicines legislation will ensure medicinal plants are identified correctly. The European Directive on Traditional Herbal Medicinal Products, which became law in 2004, requires that over- the-counter herbal remedies should demonstrate at least 30 years of safe use to qualify for registration. Herbal remedies are now being officially listed for safety and efficacy by the European Medicines Evaluation Agency (EMEA). In 2003, the Herbal Medicine Regulatory Working Group set up by the British government published a report calling for the immediate statutory regulation of all UK herbal pract¬itioners. This means that British herbalists will be regulated and acknowledged by the state and other fellow health professionals, thereby ensuring that herbal medicines, which have been tried and tested over hundreds of years, will continue to play a part in everyday healthcare.

Herbal remedies, like all medicines, must be treated with respect. There are certain conditions and combinations of treatments in which herbs may cause problems.

General cautions

During the first three months of pregnancy, avoid all medicines, herbal or otherwise, unless absolutely essential.

• Certain herbs should be avoided throughout pregnancy, so consult a qualified medical herbalist.

• Women who are breast-feeding should consult a medical herbalist before using herbal medicines.

• Do not give babies under 6 months any internal herbal (or other) medicine without professional advice.

• The elderly, because of their slower metabolism, may require less than the full adult dose.

• Do not stop taking prescribed conventional medication without first consulting your doctor.

• Some herbs interact with drugs. If you are taking a prescribed medicine, consult a medical herbalist.

Herb-drug interactions

Herbs can change the way that your body absorbs and breaks down (metabolises) drugs. They can also affect other aspects of your metabolism, e.g. heart rate and blood pressure, which can mask or exacerbate symptoms. If herbs and drugs have similar actions, the combined effect can be too strong. This list of cautions is a guide to some of the potential drug interactions and situations when herbs should be used with care. Consult a medical herbalist about herb-drug interactions and contraindications.

Coltsfoot (Tussilago farfara) in excessive doses may interfere with blood pressure treatment. Also avoid long-term use.

Garlic (Allium sativum) in medicinal doses can cause a dangerous decrease in blood-sugar levels if taken with diabetes medication. Do not take it with the blood- thinning drug warfarin or other anti-clotting medication. (Culinary amounts of garlic are safe.)

Ginkgo (Ginkgo biloba) should not be taken with warfarin or other anti-clotting medication.

Ginseng, Siberian (Eleutherococcus senticosus) can increase blood pressure, so it should be avoided by anyone with this condition.

Goldenseal (Hydrasatis canadensis) can raise blood pressure. Consult a qualified herbalist if taking beta- blocker or other antihypertensive medications, or medication to control diabetes or kidney disease. Hawthorn (Crataegus spp.) may interact with other medicines, especially those prescribed for heart conditions. Hops (Humulus lupulus) have a mild sedative effect and act as a depressive. Do not take if you have depression, breast cancer, or other oestrogen-responsive cancers. Do not take with alcohol.

Lily of the valley (Convallaria majalis) contains cardiac glycosides and may interact with other heart drugs. It should only be taken when prescribed by a qualified medical herbalist.

Liquorice (Glycyrrhiza glabra) should not be taken by anyone who is anaemic, or has high blood pressure. Schisandra (Schisandra chinensis) should possibly be avoided by those with epilepsy or hypertension.

St John’s wort (Hypericum perforatum) increases the rate at which the liver breaks down drugs, so that a drug taken alongside it may not be effective. Drugs that may be affected include indinavir and other drugs used for HIV infection, as well as warfarin, cyclosporin, digoxin, theophylline and possibly oral contraceptives. St John’s wort may also cause sensitivity to sunlight, though this is most unusual within normal dosage range.

WHEN TO CONSULT A PRACTITIONER

The UK National Institute of Medical Herbalists and the National Herbalists’ Association of Australia keep registers of trained medical herbalists. Your doctor may also be able to make a recommendation. You should consult a medical herbalist before taking herbal medicines if you are pregnant or have a serious condition such as diabetes, heart disease or high blood pressure. Do not stop taking prescribed medication without first consulting your doctor. Some herbs and drugs interact – see above before taking a herbal medicine.

Urticaria – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

Referral to an allergist and immunologist for elucidating and testing of potential triggers, life-threatening reactions, and complex management

Trace contaminants in herbal and vitamin supplements may make urticaria worse.

Tinnitus – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

Antidepressants: If patients are depressed/anxious or have severe tinnitus. No evidence one antidepressant works best. Research provides support for this treatment. Caution: Tinnitus is a side effect of antidepressant medications: SSRIs and TCAs such as amitriptyline (50 mg daily × 1 week, followed by 100 mg daily) (4)

Hospitalization is rarely indicated.

mercredi 4 décembre 2013

Venous Insufficiency Ulcers – Causes, Symptoms, Diagnosis, Treatment and Ongoing care

Most patients are treated with intensive outpatient care, except for those with acute significant cellulitis.

Treatment with antibiotics should consider culture and sensitivity results.

commercial(e) en système d'information

Entreprise :

EXPER Consulting est un cabinet de conseil offrant des services allant de la stratégie à la mise en œuvre (Organisation, Finance, Développement de Projets, …).

Pour accompagner notre croissance, nous recherchons actuellement un(e) Commercial(e) système d’information.

Dotée d’un tempérament énergique allié à un grand sens du service, vous faites preuve de diplomatie, de tact, atouts que vous souhaitez mettre à profit dans une optique à long terme, au sein d’une entreprise dynamique et dans une excellente atmosphère de travail.

Ce poste exige de réelles qualités humaines : excellent relationnel, sourire, dynamisme, rigueur, ponctualité, réactivité, sérieux et diplomatie.

Poste : Commercial(e) Système d’Information :  

Attaché à la Direction Générale, vos missions seront les suivantes :

Maîtriser les techniques de vente et de négociation.Prendre en charge la commercialisation de l'offre auprès d'une clientèle ciblée en correspondance avec la stratégie de développement du cabinet.Elaborer des propositions commerciales répondant aux besoins exprimés par les clients.Développer un portefeuille de comptes actifs, de la prospection jusqu'à la signature des affaires.Assister les clients dans la spécification technique de leurs projets d'intégration.Gérer et fidéliser votre portefeuille de clients : identification de projets, analyse de la problématique client, conseil et élaboration de recommandations, réalisation des devis, négociation des contrats, suivi de comptes, reporting.Assurer l'interface relationnelle et commerciale avec les clients jusqu'à la livraison et le règlement du projet.

Profil recherché :

Formation académique : De formation Bac + 2 minimum, avec une bonne maitrise du Français et des outils informatiques.Expérience professionnelle : expérience similaire d’au moins deux années dans la vente des logiciels de gestion (idéalement SAGE, …). Compétences personnelles : Capacités rédactionnelles, Bon relationnel, Réactivité, …

Type de contrat et salaire Net :

CDI, 2.500 à 3.000 Net + prime mensuelle selon rendement et objectif

Contact :

MAIL : experconsultinggmail [dot] com.

mardi 3 décembre 2013

cuisinière expérimentée pour maison privée

Nous cherchons sur marrakech une cuisinière polyvalente pour une maison privée. profil : - parlant français obligatoire - savoir cuisiner (cuisine marocaine & internationale) - aider au ménage - logement obligatoire avec la famille avec jour de repos dans la semaine - disponible sur marrakech - motorisée de préférence

Merci d'envoyer vos CV sur : contactprestige-competences [dot] com

Consultante en communication et marketing

Entreprise :

EXPER Consulting est un cabinet de conseil offrant des services allant de la stratégie à la mise en œuvre (Organisation, Finance, Développement de Projets, …).

Pour accompagner notre croissance, nous recherchons actuellement une Consultante Com & Marketing

Dotée d’un tempérament énergique allié à un grand sens du service, vous faites preuve de diplomatie, de tact, atouts que vous souhaitez mettre à profit dans une optique à long terme, au sein d’une entreprise dynamique et dans une excellente atmosphère de travail.

Ce poste exige de réelles qualités humaines : excellente présentation générale, excellent relationnel, sourire, dynamisme, rigueur, ponctualité, réactivité, sérieux et diplomatie.

Poste : Consultante Com & Marketing

Attaché à la Direction Générale, vos missions seront les suivantes :

Réalisation et exécution du plan marketing (autour de la base de clients existants et potentiels)Définition et mise en œuvre du plan de communication (autour de la base de clients existants et potentiels) et organisation d'évènements de communicationRéalisation des différentes tâches de marketing opérationnel (création de brochures, manuels, ...)Exécution des actions de téléprospectionGestion & évolution des contenus des supports de communication internes/externesSupport de la force de vente en génération de leads Réalisation d’une veille concurrentielle et les différents benchmarks au niveau national et au niveau international

Profil recherché :

Formation académique : un Bac+5 en Marketing et en Communication.Expérience professionnelle : expérience similaire souhaitable d’une année. Compétences personnelles : vous êtes créatif, rigoureux et organisé, vous souhaitez vous investir et relever des challenges. Vous avez le sens des priorités et êtes force de proposition.

Type de contrat et salaire Net :

CDI à partir de 3.000 Net (après un stage de pré-embauche de deux mois)

Contact :

MAIL : experconsultinggmail [dot] com

Responsable d'une plateforme téléphonique

L’entreprise Française TECECO, spécialisée dans les énergies renouvelables a développé son entreprise et a installé l’une de ses plateformes téléphoniques au Maroc.

Nous recherchons un /une responsable de la plateforme de Mohammedia , constituée d’un superviseur, une secrétaire, un technicien et environ 26 agents. Vous aurez en charge les missions suivantes :

-       Recruter le personnel

-       Superviser l’ensemble de l’équipe et des locaux

-       Formation et animation des salariés

-       Planification du travail et des objectifs de chacun

-       Superviser le reporting journalier et semestriel des résultats à remonter au siège

Véritable garant de l’efficacité de votre équipe concernant les résultats et l’implication de chacun.

Idéalement issu du milieu des énergies renouvelables, vous avez obligatoirement une expérience de superviseur ou responsable. Vous avez une organisation irréprochable, une autorité innée et un management de qualité. Vous savez motiver une équipe, trouver un personnel de qualité et former.

Nous vous proposons une rémunération stimulante de 5 000 à 15 000 dhr.

Poste à pourvoir sur Mohammedia, dès maintenant.
Envoyer CV+LM à l’adresse suivante : camille [dot] tececogmail [dot] com

Sécurité et superviseur pour adjudant chef gendarme en retraite

Maroc emploi, Recrutement au Maroc, le premier site d'emploi gratuit au Maroc

Emploi centre d'appel Maroc

Formation Maroc

Maroc Stage

Alibaba.ma

Emploi Maroc

Musicley

stage pour rédacteur web

Une jeune société du web à Fès recherche activement des stagiaires qui habitent à Fès pour une durée inférieure à 2 mois dans le cadre d'un stage conventionné.

Ce stage a pour but de produire des contenus uniques, pertinents et diversifiés, tel que la rédaction et la reformulation des articles en ciblant plusieurs  thématiques.

Votre mission est  d'effectuer plusieurs tâches annexes et participer au développement d'une société marocaine dans le domaine de communication web. Vous pourrez également profiter d'une formation de qualité.

Ce stage nécessite un profil avec ces critères indispensables :

-Diplôme : au moins Bac+2 en littérature française ;

- Meilleure capacité linguistique en français ;

- Qualité rédactionnelle sans faute d'orthographe ;

- Rigueur,  créativité et imagination pour rédiger un contenu attractif et novateur.

Nature de l’offre : Stage;
Durée hebdomadaire : mi-temps;
Lieu : Fès (Narjiss).

Si votre profil correspond  à nos critères, envoyez nous votre CV à l’adresse email : secretairewebmarko [dot] com

infographiste et secrétaire

La societé TOUCH OBJETS de publicité cherche un infographiste et secretaire ayant le profil suivant:

-Niveau: Bac+2

-Expérience: + 1an

-Bien maitriser (l'infographiste): Illustrator, Photoshop,...

lundi 2 décembre 2013

receptionniste (bilingue français -anglais)

besoin de deux réceptionnistes ( filles )

- bonne présentation

- parlant français et anglais

- sérieux dans le travail

merci d'envoyer votre cv + photo a : spa [dot] marrakechgmail [dot] com

metreur qualifié exp min 7ans

nous cherchons ( sté BTP) un metreur qualifé tous corp d'Etat expérience minimum 7 ans , merci d'adtresser votre cv à: recrutementcadrealumhotmail [dot] fr

NB.débutant s'abstenir

stage rémunéré Développeur web

Centre d'appels A RABAT cherche pour un stage rémunéré un

• Poste : Développeur web

• Vous êtes chargés de réaliser un site web dynamique autour de solutions Open Source PHP/MYSQL.

• Profil : Vous êtes diplômés(e) en informatique (Bac + 2 min). Vous maîtrisez PHP; MYSQL; XHTML/CSS. vous bénéficiez d'une première expérience dans la réalisation de site Web en PHP, Avoir l'esprit d'équipe, le bon d'esprit d'initiative, de créativité, aimer le travail, ponctuel et assidu...

Important : répondre à l'annonce en mentionnant la référence "dev-php"

• Gsm : 0663 84 80 04

• Contact e-mail : prod [dot] fidlemgmail [dot] com

commercial(e) à Marrakech

Entreprise :

MOCOBEL Maroc est spécialisée dans les domaines du génie électrique, des télécommunications et de la construction.

Poste proposé : Commercial Expérimenté à Marrakech

Mocobel Maroc recherche dans le cadre de son développement un(e) Commercial(e) expérimenté(e) dans la vente des caméras de surveillance et les systèmes de détection d'incendie à Marrakech.

Nous vous offrons :

Une rémunération attractive
Indemnités de transport
Des conditions de travail agréables

Nous répondons à toute candidature, à condition qu'elles correspondent à l'annonce et qu'elles soient complètes (Lettre de motivation + CV + photo).

Prière d'envoyer vos cv au :

recrutemocobel-maroc [dot] com / sakina [dot] mounirmocobel-maroc [dot] com

Pour plus d'informations Veuillez nous contacter au : 06.61.65.64.99 / 06.14.30.40.04

Architectes & Planners

Présente dans le monde entier, notre entreprise est spécialisée dans la realisation d'aeroport de nouvelle generations de part le monde, dans le cadre de notre developpement en Asie Sud Est, nous recherchons des architectes, planners et architectes d'interieurs.

Nous recherchons des architectes confortable dans la realisation de projets de nouvelles generations, les candidats devront avoir une capacité d'analyse, effectuer des recherches et alimenter une base de donnée architecturale, créer des bibliotheques, analyser des quantités et mettre en place des strategies d'integrations propres au developpement.

Une période de deux mois d'integration avec des semi formations sur le domaine en question seront fournies aux candidats retenus.

Limite de reception des offres : 4 Janvier 2014.

Description des profils recherchés (les profils doivent imperativement correspondre a cette requete)

PROFIL ARCHITECTES

Qualification : Architecte Spécialité : Architecture en Batiment et developpement durable sur plan type Landside (rural)Logiciel : Autocad, Autocad REVIT  Lieu de mission : Maroc avec des déplacements sur l'indonesie a prevoir.  Durée de la mission : CDI, CDD (stages possibles sur selection des responsables) Salaire : selon profilConditions Particulières : Extrait de Casier Judiciaire et Accords de confidentialité obligatoires.

PROFIL ARCHITECTES D'INTERIEUR

Qualification : Architecte d'interieur (selon les normes transmises) Spécialité : Architecture d'interieur selon les critères du green building council Logiciel : Autocad, Autocad REVIT  Lieu de mission : Maroc avec des déplacements sur l'indonesie a prevoir.  Durée de la mission : CDI, CDD (stages possibles sur selection des responsables) Salaire : selon profilConditions Particulières : Extrait de Casier Judiciaire et Accords de confidentialité obligatoires.

PROFIL PLANNERS

Qualification : Ingenieurs Civils Spécialité : Ingenieurie Civile  Logiciel : Autocad, Autocad REVIT  Lieu de mission : Maroc avec des déplacements sur l'indonesie a prevoir.  Durée de la mission : CDI, CDD (stages possibles sur selection des responsables) Salaire : selon profilConditions Particulières : Extrait de Casier Judiciaire et Accords de confidentialité obligatoires.

Ingénieur Technico-commercial

Ceci est une opportunité d’épanouissement professionnel et de progression rapide pour le bon candidat.

IMPORTANT: Seuls les candidats qui ont de grandes capacités d'adaption, sont persevants, orientés résultats et peuvent produire du chiffre d'une façon systematique doivent appliquer.

Dans le cadre du développement de nos activités au Maroc, nous recrutons un ingénieur d’affaires TI sénior spécialisé dans la vente complexe de solutions sur tout le territoire national.

Votre Mission

-Etablissement d’un plan de prospection. Etablissement d'une liste de prospects cibles.

-Prospection active et soutenue pour détecter le besoin, présenter, défendre et négocier des solutions qui représentent une importante valeur ajoutée à nos clients.

-Développement d’un portefeuille client segmenté par secteur d’activité.

-Rédaction de propositions et négociation commerciales complexes.

-Réponse aux appels d’offre et suivi méticuleux de tout le processus afin de remporter le maximum de marchés.

-Réalisation des objectifs de vente trimestriels définis par la direction générale.  

-Fidélisation des clients en proposant des contrats de maintenance et d'evolution ainsi que de nouveaux services.

Profil recherché

-De formation supérieure (Bac+2 Commerce/Vente ou Ecole de Commerce ou Ecole d'Ingénieur en Informatique)  vous témoignez d’une première expérience commerciale réussie de 1 à 3ans. Débutants sans expérience avec le bon profil sont acceptés. 

-Un sens du relationnel et un leadership naturel sont requis. Vous devez savoir convaincre.

-Une autonomie et une grande capacité à gérer son emploi du temps.

-Une aisance à traiter les objections, détecter les blocages et penser de façon non conventionnelle (Thinking outside of the box) pour conclure les ventes complexes.

-Une aptitude à évoluer, apprendre, réviser l’approche commerciale afin de mieux répondre aux besoins du marché.

-Une méthodologie de travail, une organisation, une autonomie et une rigueur sont des atouts nécessaires pour répondre au mieux aux problématiques confiées par nos clients.

-Un désir presque viceral de dépassement de soi et une capacité à toujours dépasser les objectifs fixés par la direction.

-Perséverance et patience sont des atouts requis.

Aussi :

-Une bonne connaissance des outils des outils informatiques et en particulier l’outil de gestion commerciale de type CRM.

-Intérêt certains pour les nouvelles technologies de l’information et de la communication.

Salaire et type de contrat:

Le salaire potentiel (fixe + commissions + bonus) est de 25,000Dh/Mois et peut atteindre 55,000Dh/Mois en moins de 3 ans pour les commerciaux les plus performants. Les commissions ne sont pas plafonnées

Le contrat est de type CDI.

Pourquoi nous choisir?

Notre entreprise, une SSII acteur international spécialiste dans la conception, l'intégration, la maintenance et la vente de solutions logicielles innovantes à forte valeur ajoutée pour nos clients. Avec le développement rapide du marché smartphone et tablettes, nous avons très tôt commencé le développement et l’intégration de solutions logicielles mobiles pour les entreprises; la mobilité d’entreprise.

Notre structure, en phase de forte croissance, offre un cadre de travail agréable, des outils adaptés et une collaboration enrichissante avec les autres membres tous motivés par le même objectif d’excellence et de dépassement de soi, ainsi qu’une opportunité d’avancement rapide aux postes de management.

Comment appliquer?

Envoyez votre CV + Lettre de Motivation + Réalisations Commerciales (Chiffre d’affaires réalisé, augmentation des ventes etc.. réalisées dans de précédentes expériences) à l’adresse : SSII [dot] Emploigmail [dot] com

dimanche 1 décembre 2013

Product Support Engineer (Level 2 ) (Rabat)

About our client:

Multinational Company present in several countries, leading provider of IT products and services for the global marketplace including hardware, software, networking, business solutions, and more.

Job description:

For our prestigious client we are looking for a: Product Support Engineer ( Level 2 ) IT Service Desk , to provide a second line of IT technical support and to coach service desk 1st line team for technical proficiency, participating in every aspect of service delivering, your missions revolve around the following :

-       Provide 2nd line support, and conduct quality assurance ;

-       Review and act upon daily reports ;

-       Manage 2nd line stack and user admin team and uphold desk rules and procedures ;

-       Manage joiners and leavers, provide training, install and configure tools used by the service desk ; 

-       Manage and request agents rights for the different required helpdesk’s tools and resources ;

-       Maintain and manage Knowledge Base and SharePoint and provide product training ;

-       Remote control tool assistance provide desk with needed Work instructions and First Checks ;

-       Actively participate and assume responsibilities on the Sense and Respond and Lean process ; 

-       Manage technical change and shift to the left projects ;

-       To liaise with peers to develop team dynamics.

Desired profile:

Professional Qualifications:

Engineering degree in Computer Engineering or equivalent;

ITIL certification (IT service management) or equivalent is is desirable;

English fluency;

Knowledge, Skills:

-       Knowledge and experience on Desktop technical support; 

-       Solid knowledge on Microsoft Office;

-       Solid IT knowledge (client, server, Active Directory, networking);

-       Significant knowledge of IT Infrastructure components (Exchange, Domain Controllers, File and Print  Servers, networking);

-       knowledge of Smartphones systems (Windows Mobile and Blackberry);

-       Significant competency in building and sustaining relationships at various levels;

-       Training and coaching skills. 

-        

Personal Attributes:

Planner, organiser, Enthusiastic and passionate about the role.

If your profile matches the announcement please send your resume to : sosoffshoringgmail [dot] com

Une Assistante du PDG

Groupe opérant dans le secteur du BTP positionnés parmi les leaders du marché recrute pour son siège à Casablanca :

Une Assistante du PDG

 Rattachée au PDG du Groupe, vous serez en charge d’assister le PDG  dans l’optimisation de la gestion, l’organisation de l’activité et la coordination des informations liées au fonctionnement de la structure, vous constituerez un véritable pôle de support et de coordination tant en interne qu'en externe.  

Vous avez une maîtrise parfaite de la langue française et anglaise aussi bien à l'écrit qu'à l'oral. Vous jouissez d'un sens relationnel et d'une facilité de communication avec les différentes parties prenantes du Groupe. Vous êtes autonome, rigoureuse et vous faites preuve d'une discrétion et d'un sens de l’étique irréprochable.

Vous avez les compétences nécessaires pour la préparation et le suivi des conseils d'administration et des réunions de Direction. Vous êtes familière avec la gestion des événements, des voyages et déplacements professionnels ainsi que les autres formes du support administratif aux ressources humaines.

Outre vos compétences organisationnelles et votre résolution à réaliser pleinement les tâches confiées, vous avez également une grande capacité à vous adapter à des interlocuteurs variés et à un environnement de travail multiculturel.

De formation Bac+4 (Administration/Gestion, Economie, ou Sciences Sociales), vous bénéficiez d’une expérience minimum de 5 ans dans un poste similaire. 

Intéressez, envoyez-nous votre candidature complète (CV, LM, Photo, Disponibilité, Mobilité, Prétentions)  à l'adresse email : rh [dot] bmkrecrutegmail [dot] com

lundi 25 novembre 2013

Depression Defined: Symptoms, Epidemiology, Etiology and Treatment

Depression is a term that has been used to describe a variety of ailments ranging from minor to incapacitating. Clinically significant depression, termed major depression, is a serious condition characterized not only by depressed mood, but a cluster of somatic, cognitive, and motivational symptoms. Major depression can be differentiated from a normal and transient sad mood by several factors:

intensity, as major depression causes impairment in social or occupational functioning and persists across time and situationsrelationship to antecedent events, as major depression either occurs without any identifiable antecedent event or is clearly in excess of what would be considered an expected reactionquality, with the quality of the emotion being different from that experienced in a normal sad moodassociated features, as the mood co-occurs with a group of other cognitive and somatic symptomshistory, with major depression typically appearing after a history of other such episodes (Whybrow et al 1984).

Individuals who are suffering from major depression often report feeling overwhelmed, helpless, despairing, suffocated, or numb. Major depression can range from mild sadness to complete hopelessness and is often accompanied by frequent crying spells. Those with more severe depression may feel like crying but be unable to do so. Severely depressed individuals often believe that no one can help them.

Depression is defined according to specific criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric Association (APA) 1994).

The DSM-N details the diagnostic criteria for nearly 300 mental dis-orders, and nearly 100 other psychological conditions that might be the focus of professional attention. While many individuals experiencing a debilitating depression will meet criteria for one of the disorders within the DSM-IV, some will nonetheless elude classification using this system. The following sections detail the different disorders within the DSM-IV that may involve depressive symptoms, following which an overview of etiology and treatment — for the non-specialist — is provided.

In order to be diagnosed with a major depressive episode according to the DSM-IV, an individual must have at least five out of nine possible symptoms, which must be present during the same 2-week period and represent a change from a previous level of functioning. One of the symptoms must be either depressed mood for most of the day on nearly every day, or loss of interest or pleasure (anhedonia) in all or almost all activities for most of the day on nearly every day. Additional symptoms that may accompany the depressed mood or anhedonia are:

significant weight loss (when not dieting) or significant weight gain (i.e. more than 5% of body weight in 1 month), or a decreased or increased appetite nearly every dayinsomnia or hypersomnia nearly every dayobservable psychomotor agitation or retardation nearly every dayfatigue or loss of energy nearly every day, feelings of worthlessnessor excessive or inappropriate guilt nearly every daydiminished ability to think or concentrate, or indecisiveness nearly every dayand recurrent thoughts of death (not just fear of dying) or suicide.

‘Depression is also often diagnosed according to criteria outlined in the ICD-10 Classification of Mental and Behavioral Disorders (World Health Organization 1992). ICD-10 criteria overlap substantially, but are not identical to, those of the DSM-IV. This post focuses on the criteria of the DSM-IV because the studies reviewed here have predominantly relied on these criteria for diagnosing depression.

The symptoms must be present for at least 2 weeks and cause clinically significant distress or impairment in social, occupational, or other areas of functioning. Additionally the mood disturbance should not be the direct physiological effect of a substance (e.g. street drug or medication) or general medical condition (e.g. hypothyroidism) (APA 1994). Individuals who meet criteria for a major depressive episode and have never experienced any manic or hypomanic episodes (see below) then meet criteria for major depressive disorder.

Unipolar Versus Bipolar Depression

The DSM-IV distinguishes two broad classes of mood disorder: unipolar and bipolar disorder. Unipolar disorders involve only the depressed dimension of mood and do not include periods of above-average mood such as manic or hypomanic episodes. There are two unipolar mood disorders: major depressive disorder and dysthymic disorder. Bipolar disorders include those in which the individual experiences both depressed moods and manic or hypomanic episodes. The three bipolar disorders described in DSM-IV are bipolar I disorder, bipolar II disorder, and cyclothymic disorder.

Dysthymia

Another form of depression that is less intense but more chronic than major depressive disorder is dysthymia. Distinguishing between a diagnosis of major depressive disorder and dysthymia is difficult because the two share many symptoms and the differences in onset, duration, persistence, and severity are difficult to evaluate retrospectively. In order to meet DSM-IV criteria for dysthymic disorder, an individual must experience depressed mood for most of the day, more days than not for at least 2 years. In children and adolescents, irritable mood would also suffice to meet the criteria, and must last for at least 1 year. Two or more additional symptoms must also be present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. At no time during the 2-year period has such a person been without the depressive symptoms for more than 2 months at a time. If the person has met criteria for major depression at any point during the 2-year period, the diagnosis would be considered as major depression instead of dysthymia. However, an individual who has met criteria for dysthymia for at least 2 years and then subsequently meets the criteria for an episode of major depression superimposed on the dysthymia (without an intervening remission) would be given both diagnoses. This condition is referred to as double depression. It is particularly difficult to differentiate double depression from simple major depressive disorder or chronic major depressive disorder for the reasons mentioned above, combined with the fact that all three meet criteria for a major depressive episode and they differ only in onset, duration, and persistence. A history of mania (at least one manic episode) would rule out a diagnosis of both major depression and dysthymia (APA 1994).

Mania and Bipolar Disorder

Mania is the mood state that is the apparent opposite of depression. Mania involves a euphoric or elated mood that lasts for at least 1 week. A manic episode is more than just a normal good mood; rather, the person feels like he or she is on top of the world and there is nothing he/she can’t do. The euphoric mood is accompanied by at least three other symptoms, including: inflated self-esteem or grandiose beliefs (e.g. that the patient is President or some other famous person of importance), a decreased need for sleep (i.e. feels rested after only 3 h of sleep), a pressure to keep talking, the subjective experience that one’s thoughts are racing, distractibility, increase in activity (either socially, at work or school, or sexually), and excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g. unrestrained buying sprees, sexual promiscuity, etc.). In addition, the mood disturbance must cause impairment in functioning (either social or occupational), or require hospitalization to prevent harm to self or others, or involve psychotic features (e.g. hallucinations). Furthermore, a manic episode is not diagnosed if the symptoms are caused by street drugs, medication or other treatment, or a general medical condition (APA 1994).

A person who has experienced at least one manic episode would meet the criteria for bipolar I disorder. Most individuals who meet criteria for bipolar I have also experienced episodes of major depression in addition to manic episodes; however, this is not necessary for the diagnosis.

Some individuals experience a mood disturbance called hypomania that is similar to a manic episode, but not as severe. The criteria for hypomania are the same as the criteria for a manic episode (described above); however, hypomania must only be present for at least 4 days (versus 1 week for a manic episode), and the episode must not cause impairment in functioning or require hospitalization. Individuals who have experienced at least one major depressive episode, at least one hypomanic episode, and no fully developed manic episodes would be give a diagnosis of bipolar II disorder (APA 1994).

Cyclothymia

Cyclothymia is a more chronic but less intense form of bipolar disorder. To meet criteria for cyclothymia, an individual must experience numerous periods of hypomania and depressed mood over a period of at least 2 years. In fact, the person cannot show the absence of both hypo-manic and depressive symptoms for a period of more than 2 months. Moreover, in cyclothymia there are no major depressive episodes or manic episodes during the first 2 years of the disorder (APA 1994).

Although it is possible that acupuncture may prove effective in treat-ing many varieties of depression, our previous clinical trial (Allen et al 1998) examined only major depressive disorder, and this manual is designed for use with major depressive disorder. With modifications, it is possible that the framework detailed in the subsequent posts could be adapted for use with other depressive disorders.

Specifiers of Major Depression

To capture more adequately the range of mood disorders, the DSM-IV additionally provides for the inclusion of specifiers, which can be used to describe the current or most recent major depressive episode included. These specifiers include chronic, with melancholic features, severe with psychotic features, postpartum onset, and atypical. In addition, the course of the disorder can be specified as `with seasonal pattern’, which is considered a subtype of major depression also known as seasonal affective disorder. The bipolar disorders can be specified as rapid cycling.

The costs of major depression are substantial, and exceed those of other chronic diseases such as diabetes and hypertension in terms of personal distress, lost productivity, interpersonal problems, and suicide. A recent study estimated that these annual costs of depression in the United States exceeded $40 billion (Hirschfeld & Schatzberg 1994), and similar findings have emerged from a worldwide study (Murry & Lopez 1996) that ranked unipolar major depression as the number one cause of disability in the world. Over 80% of individuals who committed suicide were clinically depressed in the months before their death, and the lifetime risk for suicide among those with clinical depression is 15% (Hirschfeld & Schatzberg 1994). Furthermore, depressed individuals appear to be at increased risk of death from all causes. A 16-year prospective study found that mortality rates for depressed individuals are 1.5-2 times those of nondepressed individuals (Murphy et al 1987). Clearly, depression is a prevalent disorder with costly and potentially lethal consequences (Gotlib & Beach 1995).

Comorbidity of Major Depression with other Mental Disorders

Comorbidity is the presence of two or more disorders simultaneously. Comorbid conditions are generally more chronic, do not respond as well to treatment, and have a poorer prognosis than single disorders. It is important to be aware of the issue of comorbidity because a large proportion of individuals in the general population have more than one mental disorder concurrently (Kessler et al 1994). Outcome studies usually examine efficacy for individuals with only one disorder. Therefore, the average clinician deals with much more complicated cases than outcome research addresses (Greenberg & Fisher 1997). In fact, the National Comorbidity Survey found that it was more common to have two or more mental disorders than to have only one (Kessler et al 1994).

Dysthymia is present before the onset of a major depressive dis-order in approximately 10% of epidemiological samples. Other forms of mental illness may be present concurrent with major depressive disorder, such as: alcohol abuse or dependence disorder, personality disorders (e.g. borderline personality disorder), panic disorder, and other anxiety disorders (APA 1994). The literature demonstrates that 33-59% of people who are dependent on alcohol eventually meet criteria for depression at some point during the dis-order (Merikangas & Gelernter 1990). The comorbidity of personality disorders in clinically depressed individuals is 50% or greater (Zimmerman et al 1991). The comorbidity of anxiety disorders with depression is particularly high, in the range of 30% (Hiller et al 1989) to 57% (Mannuzza et al 1989). Research demonstrates that between 15 and 30% of individuals with acute major depression also suffer from panic disorder concurrently (Brown & Barlow 1992). The diagnostic criteria of anxiety and depression overlap, which increases the probability of meeting criteria for both disorders simultaneously. This overlap makes it difficult to know whether there exist two separate classes of conditions — anxiety and depression — or whether there may exist a single underlying predisposition that manifests with both depression and anxiety symptoms (see Frances et al 1992). In addition, the overlap increases lifetime comorbidity (i.e. meeting criteria for both depression and an anxiety disorder) between the disorders (Klerman 1990). The comorbidity of anxiety disorders with depression poses a taxonomic enigma (see Frances et al 1992) for diagnosticians and those interested in etiology.

In addition, 20-25% of individuals with general medical conditions such as diabetes, myocardial infarction, carcinoma, and stroke meet criteria for major depressive disorder at some point during the course of their illness (APA 1994). Depression may occur in the context of medical illness for three reasons: (1) the depression appears to represent a reaction to the burden and limitations associated with having a disease, (2) the depression is unrelated to the disease, but is a recurrence of a long-standing history of depression, or is in response to some other event in the person’s life, or (3) the depression occurs as a direct physiological consequence of the medical condition (e.g. mul-tiple sclerosis, stroke, hypothyroidism). In this latter case the diagnosis is technically not major depressive disorder, but rather mood disorder due to a general medical condition. A mood disorder can also be directly etiologically related to the use of a medication or a drug of abuse. In that case a diagnosis of substance-induced mood disorder (e.g. cocaine-induced mood disorder) is made instead of major depressive disorder. However, this diagnosis is reserved for depression that is a direct physiological consequence of the drug abuse or medication use; for example, the depressed mood is only present following withdrawal from cocaine (APA 1994).

This latter determination is often difficult to make because of the high rates of comorbid substance abuse or dependence disorders and mood disorders. In some cases individuals may begin using substances in response to depression, in an unfortunate attempt to cope with their pain. In such a case, major depression would be comorbid with sub-stance abuse, and both diagnoses would be given. In other cases, it could be that a pre-existing substance abuse disorder appeared to cause the depression through direct physiological means (e.g. cocaine withdrawal), in which case the diagnosis would be substance-induced mood disorder (see DSM-IV for further clarification of these diagnostic issues).

A variety of well-researched treatments exist for depression, and most have rather favorable results. These treatments include both psychotherapies and drug therapies. Unfortunately, however, the effectiveness of these traditional treatments is hampered by high rates of dropout, recovery failure, and relapse, suggesting that these traditional treatments may provide insufficient or transient symptom relief for many.

The National Institutes of Mental Health Treatment of Depression Collaborative Research Program was a clinical trial designed to investigate the efficacy of two brief psychotherapies (interpersonal psychotherapy and cognitive behavior therapy) and a drug treatment (pharmacotherapy with imipramine hydrochloride, a tricyclic antidepressant), all compared with a control group consisting of clinical management combined with pill-placebo as treatments for major depression. In this NIMH treatment study, 32% of patients who were randomized to treatment discontinued treatment prematurely. Excluding patients who dropped out for external reasons or because they had improved, 25% of all patients entering treatment terminated due to negative effects of the treatment such as dissatisfaction with treatment, desire for another treatment, intolerable side effects, and noncompliance (Elkin et al 1989). Among patients who had completed 15 weeks of pharmacotherapy or psychotherapy (not including the placebo group), 43-49% failed to recover to the point of having few symptoms, and among all patients including completers and non-completers 30-64% did not have significant symptom relief at the end of treatment (Elkin et al 1989).

Advocates of standard antidepressant medications (e.g. tricyclics such as imipramine) generally acknowledge that about one-third of patients do not improve with medication, one-third display improve-ment with placebos, and the remaining third demonstrate improve-ment that would not occur with placebo (Greenberg & Fisher 1997). In a meta-analysis (a statistical literature review that has compressed the results of large numbers of studies) of antidepressant outcome in which clinician bias was minimized, Greenberg et al (1992) found that effect sizes were approximately one-half to one-quarter as large as those found in previous studies in which clinician bias was not minimized. Clinician bias was reduced by examining the effectiveness of standard antidepressant tricyclic medications compared with newer antidepressants (serotonin reuptake inhibitors; SSRIs) as well as a placebo control. Presumably, in studies with such a design there is less motivation to establish the efficacy of the standard antidepressants, yet their effects can still be compared with those of a placebo control. With the advent of a new generation of antidepressants (SSRIs), it was hoped that they would be superior in treating depression to the older medications. A meta-analysis of all of the double-blind placebo-controlled efficacy studies of fluoxetine (Prozac) found that it was modestly effective in treating depression and resulted in response rates similar to those obtained in previous meta-analyses of tricyclic antidepressants (Greenberg et al 1994). Other meta-analyses and reviews have also found that new-generation antidepressants have equivalent outcomes to tricyclics (e.g. Anderson & Tomenson 1994, Edwards 1992, 1995, Kasper et al 1992).

It has been suggested that there may be some preference for SSRIs over tricyclics because they cause less sedation and fewer anticholinergic effects and cardiac complications than the standard tricyclics; however, they are associated with other side effects such as nausea, diarrhea, weight loss, agitation, anxiety, and insomnia (Edwards 1995; see below for details about the side effects of tricyclics, monoamine oxidase inhibitors (MAOIs), and SSRI antidepressants). Although drop-out rates from medication treatment studies are high regardless of the type of antidepressant used, the side effects of SSRIs may be slightly better tolerated by some people. These differences in tolerability are very small and may not be clinically meaningful. Furthermore, the number of patients completing each type of treatment is approximately equivalent (Greenberg & Fisher 1997).

The average effect in psychotherapy outcome research is one standard deviation, which is statistically large. An effect size of one standard deviation means that the average person receiving psychotherapy is better off than 84% of the people in the control condition who did not receive psychotherapy. In five meta-analyses of outcome with depression, psychotherapy outperformed no-treatment and wait-list controls (Lambert & Bergin 1994). Effect sizes produced by psychotherapy are equal to or greater than effects produced by various medical and educational interventions (Lambert & Bergin 1994).

For example, psychotherapy is as effective as or more effective than antidepressant medication (Dobson 1989, Robinson et al 1990, Steinbrueck et al 1983). When the allegiance of investigators and the differences between treatments are taken into account, the effectiveness of psychotherapy and pharmacotherapy is equivalent (Robinson et al 1990, Steinbrueck et al 1983). The results of the NIMH Collaborative Depression study, the largest and most well-controlled psychotherapy study conducted to date, support this notion. The NIMH study utilized investigators who were committed to each type of therapy compared and found little evidence for significant differences between therapies (Elkin et al 1989).

These findings are significant because antidepressants are often considered the treatment of choice for depression. Evans and colleagues (1992) found that psychotherapy may have an advantage over antidepressants in terms of decreased vulnerability to relapse. In addition, psychotherapy is not accompanied by the somatic side effects that occur with antidepressants. However, there is some evidence that antidepressants may start to work faster than psychotherapy and may be more effective with endogenous depressions ( Lambert & Bergin 1994 ).

Relapse, Recurrence and the Role of Maintenance Treatments

Depression tends to be a chronic and recurrent disorder. A naturalistic study of depression found that 70% of people recover from depression after 1 year and 81% after 2 years. Unfortunately, 12% of depressed individuals do not recover until 5 years after the onset of the episode and 7% of individuals suffering from depression remain chronically depressed (Hirschfeld & Schatzberg 1994).

Even once successfully treated, depression is likely to recur. Without further treatment, one-fifth of previously recovered persons once again meet criteria for major depression 6 months after the completion of treatment, and nearly one-quarter will develop new depressive symptoms. Within 18 months, over one-third of those persons who were remitted will once again meet criteria for full depression (Shea et al 1992). Ten years after an initial episode, 76% of patients will have a recurrence of depression. For those who have experienced two episodes, there is an 80-90% chance of experiencing a third episode (Hirschfeld & Schatzberg 1994). A growing consensus among those who treat depression is that, after recovery, some form of continued maintenance treatment is necessary.

Whereas research into the pharmacotherapy of depression has provided ample data concerning response to acute treatment, much less is known about the long-term efficacy of antidepressants. The available data suggest that a substantial proportion (10-34%) of patients who have responded to pharmacotherapy experience a return of depression during continued treatment (Belsher & Costello 1988, Doogan

Caillard 1992, Evans et al 1992, Frank et al 1990, Montgomery et al 1988, Prien & Kupfer 1986, Prien et al 1984, Robinson et al 1991, Thase 1990). Even greater recurrence rates are reported during long-term treatment for more severe depression. For example, Prien et al (1984) reported a 52% recurrence rate in patients on imipramine and Glen (1984) reported 68-70% recurrence rate in those on amitrip-tyline or lithium. Taken together, these data highlight the recurrent nature of mood disorders even during the course of long-term treatment and magnify the importance of developing alternative approaches for both short- and long-term treatment of depression.

Only a few studies have examined the effectiveness of psychotherapy maintenance — continued treatment designed to help keep a person from returning to a depressed state. These studies indicate that maintenance psychotherapy (alone or in combination with pharmacotherapy) helps to prevent or delay relapse or recurrence of depression. Based on a limited number of studies, cognitive therapy appears to be an effective maintenance treatment and may delay the onset of subsequent episodes of depression (Blackburn et al 1986). Although following a 6-month continuation phase relapse rates did not differ between cognitive therapy, cognitive therapy plus antidepressant drug of choice (typically amitriptyline or clomipramine), and antidepressant-alone groups, those participants receiving cognitive therapy (alone and in combination with antidepressants) had a significantly lower relapse rate than patients receiving antidepressants alone. Even without maintenance, similar results were obtained in a 2-year follow-up (Evans et al 1992). At the end of a 2-year follow-up in which no maintenance treatments were provided, patients who had received cognitive therapy (with or without medication) had significantly lower relapse rates (21% and 15%) than those who had received antidepressants only (50%) during a 3-month acute treatment phase. Another group that was continued on antidepressants for the first year of follow-up had an intermediate relapse rate (32%), which did not differ significantly from that of the other groups. Limited sample sizes (10 to 13 per group), however, make interpretation of the nonsignificant difference precarious. Collectively, these findings suggest that cognitive therapy is at least as effective as antidepressant medication in preventing relapse or recurrence.

There are also indications that interpersonal psychotherapy (IPT) provides some benefit as a maintenance treatment. An 8-month maintenance study (Klerman et al 1974) found that weekly IPT produced lower relapse rates (17%) than placebo combined with monthly 15-min IPT sessions (31%). The group receiving IPT weekly performed almost as well as the groups receiving amitriptyline and monthly IPT (12% relapse) and the amitriptyline combined with weekly IPT group (12.5% relapse). A 3-year maintenance study (Frank et al 1990) found that IPT alone, given once a month, had a recurrence rate of 60%, a rate between that of the medication groups and the placebo group. It should be noted, however, that imipramine maintenance was given in a much higher dosage than in any previous maintenance study and IPT was given in a much lower dosage (monthly) than found effective in previous studies. Nonetheless, the IPT maintenance treatments significantly lengthened the mean time of remission (survival rate) to over 1 year, compared with the placebo group with a mean duration of remission of 38 weeks.

Psychological Theories

Depression undoubtedly has many causes, and no single cause is likely to provide an adequate explanation. Different individuals may have different factors that contribute to their depression, and for any given individual multiple factors will contribute. Below we discuss some of the most widely researched factors that are thought to contribute to depression.

Learned Helplessness

The learned helplessness model posits that feelings of helplessness underlie depression. This model is based on research with both humans and animals, and has detailed how animals and humans learn that their efforts do not affect their situation and as a result they give up. Learning that behavior does not influence the situation causes motivational, cognitive, and emotional changes that resemble those in depression (Seligman 1975). Humans learn to feel helplessness not only by being in an uncontrollable situation, but also by coming to expect that their behavior will not affect important outcomes. When individuals stop expecting their responses to have an effect, they may cease trying. They have little motivation to try to escape or change situations because they have learned that nothing will change, despite their efforts. Learned helplessness also diminishes the chances that a person will later learn that responses do alter a situation. For example, dogs that were placed in a shuttle box and exposed to unavoidable inescapable shock later failed to attempt an escape when they were placed in a shuttle box in which they could escape the shock by jumping over the barrier. Learned helplessness produces affective deficits because an individual experiences negative cognitions as a result of learned helplessness (Abramson et al 1978).

The theory was revised when research demonstrated that most people do not become depressed when they experience an uncontrollable negative event. According to the reformulated theory (Abramson et al 1978), some people demonstrate a `depressogenic’ attributional style in which they explain negative events using internal, stable, and global reasons. Individuals can make either internal or external attributions about the reasons for negative events (e.g. it was my fault versus it was someone else’s fault). Those who make internal attributions are likely to suffer a loss of self-esteem because they feel that the uncontrollable situation stems from their inadequacy, whereas those who make external attributions believe their helplessness is a result of the situation and realize that the situation will change (Abramson et al 1978).

Another factor that affects an individual’s emotional reaction to an event is whether he or she generalizes the helplessness to all situations (makes a global attribution) or specifies that the helplessness occurs only in this particular situation (makes a specific attribution) (Abramson et al 1978). If individuals believe the negative event is due to a transitory factor (e.g. they failed the test because they did not feel well), they will make an unstable attribution that will result in only a short-lived depressive reaction. In contrast, a stable attribution about something that is unlikely to change will result in prolonged negative feelings about the event; for example, they failed the test because they are stupid (Abramson et al 1978). Research has demonstrated that an internal, stable, and global attributional style is a marker for vulnerability to depression (Seligman & Nolen-Hoeksema 1987).

Cognitive Model of Depression

According to the cognitive model of depression (Beck 1976), individuals become depressed because of inaccurate information processing that causes them to interpret events in a biased way. These negative but incorrect beliefs involve negative views of self, a negative world view, and pessimistic future expectations. These beliefs lead to behaviors that serve to reaffirm the beliefs. Furthermore, once they become depressed, individuals tend to focus selectively on negative thoughts, which cause them to perceive themselves and their situation in the worst possible light. This negative bias contributes to the maintenance of the depressed mood (Hollon & Garber 1988). Negative cognitions are viewed as necessary but not sufficient to trigger depression. They interact with other predisposing factors such as genetics, developmental factors, and traumatic events to trigger depression in certain individuals.

Gender Differences in Depression

The incidence of unipolar depression in women is approximately twice as high as the rate in men. According to Nolen-Hoeksema (1987), women tend to ruminate in response to depressed mood, amplifying and sustaining it, and men tend to cope with depressed mood by engaging in active behavior, which serves to inhibit their dysphoria. These differences in coping style may stem from social pressure on men to be active and ignore their moods, whereas women are socialized to be emotional and contemplative (Nolen-Hoeksema 1987).

Rumination contributes to depression by interfering with problem-solving behavior, which can lead to failure, feelings of helplessness, and exacerbation of the depressed mood. In contrast, active behavior can increase feelings of control, create reinforcement, and dampen depression. Furthermore, rumination increases an individual’s focus on negative memories, and activates depressive explanations of the negative feelings, which in turn lead to decreased activity, increased chances of subsequent failure, and a perpetuation of feelings of depression and helplessness (Nolen-Hoeksema 1987).

Interpersonal Factors and Social Skills

Another factor believed to be important in buffering an individual from the effects of loss and other stressful life events is social support. Having few supportive social relationships, a small social network, and few close relationships are associated with increased depression. In addition, there is evidence to suggest that the supportiveness of the most intimate relationship plays the biggest role in buffering an individual from depression, and that other supportive relationships cannot make up for deficiencies in one’s closest relationship (Coyne et al 1991).

Depression arises when negative life events lead to disappointment in expectations, personal goals, or plans. Marital discord is one example of such a stressor. Hammen (1991) has conducted longitudinal research in which she investigated individuals who were achievement focused and individuals who were socially focused. She found that individuals who experienced a life event that was considered a setback in the area of self-esteem focus were more likely to become depressed than those who experienced a setback in a domain that they were less invested in. One of the risk factors for depression is whether an individual experiences a negative life event that leads to a loss of self-esteem in an important area (e.g. an individual who derives most of her self-esteem from interpersonal relationships may become depressed when she experiences marital difficulties with her partner).

The negative life event may, in turn, cause the individual to experience reduced positive reinforcement and an increase in negative mood.

The negative experience can trigger a negative self-focus that leads to self-criticism, unfavorable evaluations of one’s own performance, blaming oneself for negative events, and negative expectations for the future.

There are behavioral consequences of self-focused attention, such as social withdrawal and interpersonal difficulties. Moreover, negative expectations may cause decreased effort and persistence on tasks. The overall effect of the self-esteem-damaging event can create conditions that perpetuate depression (Lewinsohn et al 1985).

Coping skills, such as the ability to see setback as opportunity (e.g. individuals who view losing their job as an opportunity to find a better job), can buffer the individual from loss of self-esteem. In addition, individuals who are able to decrease their self-focus by engaging in a distracting activity may be able to activate problem-solving skills rather than becoming caught up in rumination. Therefore, individuals who have predisposing characteristics (e.g. a confiding relationship or high learned resourcefulness) that permit them to cope effectively with a stressor will be able to stop the depressed feelings before they lead to a depressive episode, whereas those who lack these immunity factors or who have vulnerability factors may not be able to interrupt the depression feedback loop.

There is a complex interaction between predisposing characteristics and negative life events such that the presence of certain immunities may protect an individual from depression in spite of other vulnerability factors and, conversely, a particular combination of vulnerabilities may counteract the positive effect of an immunity factor. An individual’s predisposing characteristics, both immunities and vulnerabilities to depression, mediate the reaction to stressful life events so that in some individuals these events lead to a disruption in expectations or plans and create depression, whereas other individuals can compensate for losses and interrupt the path to depression.

Biological Theories

Research suggests that both psychological and biological factors are important in contributing to the onset of depression. People who are depressed often show signs of dysregulation of circadian rhythms (e.g. greater depression at certain times of the day), sleep disturbance, and alteration of eating habits. Psychological events can trigger this dysregulation and the depression that follows may be accompanied by altered psychological thought processes as well as maladaptive biological changes (Shelton et al 1991). It can be challenging, however, to establish whether depression is linked to a particular event. Even when there is a precipitating event, this can change as the depression continues. There are frequently clear triggers for an initial episode of major depression but not for later episodes (Brown et al 1994). Currently there is no solid evidence that certain types of depression are caused ‘biologically’ and others ‘psychologically’, and there is some evidence to the contrary (Rush & Weissenburger 1994). There is, however, evidence that treatments that alter biological rhythms, such as sleep deprivation, decreasing time spent in rapid eye movement (REM) sleep, and receiving light therapy, can relieve symptoms in many depressed individuals (Shelton et al 1991). These findings led to the development of the dysregulation hypothesis of depression.

Depression as Dysregulation

Individuals have `zeitgebers’ (time-givers): personal relationships, social demands, and behaviors that keep biological rhythms regulated normally. For example, one has to wake up at a certain time to go to work. Ehlers et al (1988) believe that these social interactions are the important link between psychological and biological aspects of depression. If a person loses social reinforcement — perhaps through death of a loved one or loss of a job — there is a resulting dysregulation of biological rhythms resulting in symptoms (e.g. mood disturbance, sleep disturbance, eating disturbance, psychomotor changes, and fatigue) that we call depression. In addition, treatments that reset the ‘biological clock’ are effective in alleviating depression in many individuals. Moreover, there are high rates of depression in people who work swing shift or night shift, who are more likely to experience disturbances in their biological rhythms.

Genetics

There is a hereditary component contributing to the predisposition to develop a mood disorder. Family studies demonstrate that first-degree relatives of those with major depressive disorder are 1.5-3 times more likely to develop depression than the general population. The risk for first-degree relatives of patients with bipolar disorder is 10 times the risk for the general population (Strober et al 1988).

Twin studies indicate that bipolar disorder is more heritable than major depressive disorder. In addition, the fact that there is a higher concordance rate between monozygotic (identical) twins than between dizygotic (fraternal) twins for major depression (40% versus 11%) and bipolar disorder (72% versus 14%) supports the heritability of depression in general (Allen 1976). An adoption study conducted by Mendlewicz & Ranier (1977) found that 31% of biological parents of bipolar adoptees had mood disorders, compared with 2% of the bio-logical parents of normal adoptees. Another study (Wender et al 1986) found that biological relatives of those with a broad range of mood disorders were eight times more likely to have major depression than biological relatives of individuals who were not diagnosed with any mood disorders.

Neurotransmitter Function

It has been hypothesized that abnormal levels of, or function of, neurotransmitters such as norepinephrine (NE), dopamine, and serotonin are a possible cause of depression. It was originally believed that decreased levels of NE contributed to the development of depressive symptoms. This is unlikely to be the mechanism, however, because most antidepressant medications take several weeks to have an impact on depression, but they have an immediate effect on blocking the reuptake of NE and other neurotransmitters. Research suggests that antidepressants may work by increasing the sensitivity of the postsynaptic receptors for NE, which appear to be under-sensitive in depressed individuals (Siever & Davis 1985). Furthermore, research indicates that serotonin dysregulation is also involved in the onset of depression. L-Tryptophan, an amino acid involved in the synthesis of serotonin, is an effective treatment for both mania and depression (Prange et al 1974). Prange and col-leagues have proposed a combined norepinephrine—serotonin hypothesis which states that: (1) a serotonin deficiency increases vulnerability to mood disorder, and (2) when there is a serotonin deficiency, too much NE will result in mania, and too little NE will trigger depression (Prange et al 1974).

Psychological Treatments

The most widely used treatments for depression include psychotherapy and antidepressant treatment. Until recently, antidepressants were considered to be a more effective treatment than psychotherapy. Psychotherapy, however, appears to produce outcomes equivalent to those obtained with antidepressants (Elkin et al 1989), and with fewer side effects. In addition, there is some evidence that psychotherapy may protect against or delay relapsing after treatment has stopped (Evans et al 1992).

When choosing a treatment for a patient, it is important to keep in mind his or her preferences and personality characteristics. Individuals are more likely to respond to a preferred treatment because they believe that it will work, and are less likely to discontinue the treatment. Certain individuals may be more likely to respond to one or another treatment, although the current state of knowledge does not assist in selecting the most effective treatment on the basis of assessing patient characteristics.

Interpersonal Psychotherapy

IPT is directed towards helping individuals interact more effectively with others. It focuses on the individual’s history of maladaptive behaviors that have created negative interactions, and seeks to alter those behaviors, thoughts, and feelings in order to result in more positive relationships. It also looks for links in the present behavior to past experiences in childhood that may have caused the patient to learn those ineffective social skills. Together, the patient and therapist explore the problems and attempt to alter the behavior and consequently relationships over time (Ehlers et al 1988). Research suggests that IPT is an effective treatment for depression and is as effective as antidepressant treatment and other forms of psychotherapy (Elkin et al 1989).

Cognitive Therapy

Cognitive therapy aims to change patients’ maladaptive belief systems to create more acceptable reactions to people and healthier interpretations of situations (Ehlers et al 1988). The patient and therapist explore the patient’s negative beliefs and the patient engages in hypothesis-testing activities to disconfirm his or her erroneous views (Hollon & Garber 1988).

The patient and therapist engage in a dialogue to define the problem, help the patient identify his or her assumptions, determine the importance of events to the patient, and point out the disadvantages of retaining the biased beliefs and maladaptive behaviors. The patient develops new skills that teach him or her to alter negative thoughts and become more independent (Corsini & Wedding 1989).

The main goal of cognitive therapy is to teach patients to alter their faulty information processing so that they interpret events in an adaptive way. The therapist aims to help patients develop new skills which they can use to prevent a recurrence of the depression. In final sessions the patients are asked to imagine themselves in difficult situations and decide what they would do if such an instance arose (Hollon & Garber 1988). Research suggests that cognitive therapy is as effective as antidepressant treatment and other forms of psychotherapy in treating depression (Elkin et al 1989).

Biological Treatments

Antidepressant Treatment

Tricyclic medications are commonly used to treat depression (e.g. imipramine and amitriptyline). The mechanism of tricyclic agents is to block the reuptake of neurotransmitters (especially NE and dopamine) from the space between the neurons in the brain (synaptic cleft). Numerous controlled double-blind research studies have demonstrated that tricyclics have efficacy in the treatment of depression (Goodwin 1992). Like most antidepressant medications, tricyclics take approximately 2-3 weeks to affect the depression (Delgado et al 1992).

Monoamine oxidase inhibitor (MAOI) antidepressants began to be used about the same time as tricyclics, but they are not as widely used. MAOIs may cause high blood pressure when used in conjunction with foods that contain tyramine (e.g. cheese and chocolate). Some early research indicated that they are not as effective as tricyclics; however, a recent review concluded that when used with a proper diet they are an effective treatment for depression (Larsen 1991).

Selective serotonin reuptake inhibitors (SSRIs; e.g. Prozac and Zoloft) are a relatively new class of drugs synthesized in the early 1980s. They work by blocking the reuptake of serotonin so that increased levels remain in the synaptic cleft. They have a high selectivity for blocking serotonin reuptake receptors, whereas tricyclics affect to a greater extent both NE and other neurotransmitters. SSRIs are currently the most frequently prescribed medication. Controlled trials suggest that they are equivalent in effectiveness to the tricyclics; however, they have fewer side effects, are more easily adjusted to the proper dosage level, and are less toxic if the patient overdoses (Greenberg & Fisher 1997). Table 3 summarizes each type of medication, side effects, and mechanism of action.

Electroconvulsive Therapy (ECT)

ECT is usually administered to inpatients in a series of treatments. Treatment frequency is approximately twice a week. Many people demonstrate marked improvement after six to eight sessions, but some need more. Electrodes are placed either on both sides of the head or at the front and back of the skull on one side of the head. ECT remains an effective treatment according to several studies (Consensus Conference 1985), although the mechanism through which it works is still unknown (Sackheim 1989). ECT is usually reserved for severely depressed patients who have not responded to other forms of treatment or who are at immediate risk of suicide. ECT may also be more effective than medication with rapid cycling bipolar patients and depressed patients with psychotic symptoms. Although infrequent, ECT can result in pervasive and persistent memory loss. More frequently, it results in minor memory loss for events that happen shortly before receiving treatment, but does not result in persistent memory loss.

Some clinicians believe that certain types of depression have a biological etiology and others have a psychological etiology. The literature suggests, however, that there are a number of different possible causes of depression, each involving a complex interaction between biological, psychological, and social factors. No one perspective provides a complete explanation for how depression develops. Regardless of how the episode appears to be precipitated, the causal mechanisms are affected at all three levels: biological, psychological, and social. While medications seem to intervene at a biological level and psychotherapy treats depression at a psychosocial level, both interrupt the chain of events that maintains the depression and both facilitate changes in the other domains. For example, antidepressants affect neurotransmitter receptor sensitivity but also affect how individuals interact with others once they begin to feel better. Psychotherapy initially targets behavior change or cognitive change (e.g. socializing with others or learning not to make minor setbacks into devastating events), which then triggers physiological changes as well.

It is important to remember that the cause of depression cannot be explained with a simple biological or psychological explanation alone. The likelihood that any given individual becomes depressed is the result of a complex interaction of heredity, physiology, environmental events, cognitive representations, and situational factors. Treatment can intervene at any point in this complex web and have effects on function across all arenas. In this early stage of research into the effectiveness of acupuncture, it is important to keep in mind that the impact of acupuncture may be seen in physiological, psychological, and social domains, but that such effects do not address the ultimate question of precisely how acupuncture works in the treatment of depression.

Actions of N-Acetylcysteine in the Central Nervous System – Implications for the Treatment of Neurodegenerative and Neuropsychiatric Disorders

N-Acetylcysteine (NAC) is the N-acetyl derivative of cysteine, and is less reactive, less toxic, and less susceptible to oxidation than cysteine, as well as being more soluble in water. For these reasons it is a better source of cysteine than the parenteral administration of cysteine itself [1]. NAC is rapidly absorbed, with time to peak plasma levels (tmax) being 1.4 ± 0.7 h following oral administration. The average elimination half-life (t1/2) has been reported to be 2.5 ± 0.6 h [2]. The bioavailability of NAC increases according to the dose, with the peak serum level being on average 16 µmol/L after 600 mg and 35 µmol/L after 1200 mg [3]. When taken orally NAC is readily taken up in the stomach and gut and sent to the liver where it is converted almost entirely to cysteine and used for glutathione (GSH) synthesis [4]. Cysteine that is not converted to GSH is capable of crossing the blood–brain barrier by means of sodium-dependent transport systems [5].

The endogenous tripeptide GSH is the most abundant low-molecular-weight thiol in human cells and plays a central role in antioxidant defense from ROS [6] as well as protection against toxic compounds [7]. GSH is synthesized in tissue from the amino acids L-cysteine, L-glutamic acid, and glycine, where the availability of cysteine is generally the rate-limiting factor in its production [8]. Across a number of studies, supplementation using NAC has been found to be an effective way of increasing intracellular GSH levels, in clinical cases of deficiency [9–11] as well as amongst healthy volunteers [12]. Due to its effectiveness in raising GSH levels and protecting the human body from oxidative stress and toxins, NAC supplementa-tion has been investigated as a treatment for a wide number of conditions including paracetamol intoxication, HIV, cancer, radiocontrast-induced nephropathy, and chronic obstructive pulmonary disease [6]. There is evidence to suggest that in Alzheimer’s disease (AD), GSH levels are decreased in both cortical areas and the hippocampus [13]. For this reason NAC may play a neuroprotective role by restoring GSH levels to a normal state.

In vitro research by Chen and colleagues [14] revealed that pretreatment of cortical neurons with NAC protected mitochondrial function and membrane integrity under conditions of oxidative stress. Similarly, Olivieri and colleagues [15] found a neuroprotective effect for NAC in neuroblastoma cells exposed to oxidative stress. Pretreatment with NAC resulted in a reduction in oxidative stress resulting from exposure to amyloid-O proteins, as well as a reduction in phosphotau levels. Research by Martinez and colleagues [16] revealed that aged mice fed NAC for 23 weeks performed better on a passive avoidance memory test than age-matched controls. Furthermore, lipid peroxide and protein carbonyl contents of the synaptic mitochondria were found to be significantly decreased in the NAC-supplemented animals compared to the controls.

Mice deficient in apolipoprotein E undergo increased oxidative damage to brain tissue and cognitive decline when maintained on a folate-free diet. Tchantchou et al. [17] found that dietary supplementation with NAC (1 g/kg diet) alleviated oxidative damage and cognitive decline, and restored GSH synthase and GSH levels to those of normal mice. There is also evidence to suggest that NAC supplementation may

bring about a reduction in amyloid-O formation. In an animal model of AD using 12-months-old SAMP8 mice with an overexpression of the amyloid precursor pro-tein, Farr et al. [18] found chronic administration of NAC to bring about significantly improved memory performance on the T-maze avoidance paradigm and lever press appetitive task. In an animal model of AD using TgCRND8 mice, Tucker et al. [19] found chronic treatment of NAC for 3 months to result in a significant reduction of amyloid-O in cortex. Similarly, research by Fu et al. [20] revealed that mice with amyloid-O peptide intracerebroventricularly injected performed significantly better in behavioral tests of memory and learning when pretreated with NAC in compari-son to those without pretreatment. NAC pretreatment was also found to significantly reverse reductions in GSH and ACh.

While considerable experimental evidence exists for the neuroprotective role of NAC, there is currently a scarcity of clinical studies examining its efficacy in the treatment and prevention of dementia. One such study, a double-blind clinical trial of NAC in patients with probable AD was conducted by Adair and colleagues [21]. Forty-three patients were randomized to either placebo or 50 mg/kg/day NAC for 6 months and tested at baseline as well as at 3 and 6 months on MMSE as well as a cognitive battery. NAC supplementation was not found to be associated with significant differences in MMSE scores compared to placebo at either 3 or 6 months; however, patients receiving NAC showed significantly better performance on the letter fluency task compared to placebo, as well as a trend toward improvement in performance on the Wechsler memory scale immediate figure recall test. Further, ANOVA using a composite measure of cognitive tests favored NAC treatment at both 3 and 6 months.

In a 12 month open-label study of the efficacy of a nutraceutical and vitamin formulation in the treatment of early-stage AD, Chan et al. [22] administered 600 mg of NAC daily as part of a larger formulation of substances including ALCAR, alpha-tocopherol, B6, folate, and S-adenosyl methionine to 14 community-dwelling individuals. Participants were found to be significantly improved on the dementia rating scale (DRS) at both 6 and 12 months, with an overall improvement of 31%. However, a limitation of this study was that no placebo group was used for comparison, although the authors claim that the efficacy of their nutraceutical formulation exceeded that of historical placebos in previous studies of mild-to-moderate AD. In a follow-up study by the same group [23], the efficacy of the same nutraceutical formulation containing NAC was tested in a group of 12 nursing home residents with moderate to late-stage AD over a 9 month period. This time participants were randomized to either treatment or placebo. The nutraceutical formulation was found to delay cognitive decline as measured by the DRS for approximately 6 months, whereas in the placebo group a similar rate of decline was observed at only 3 months. While it is difficult to differentiate the efficacy of NAC from the other substances included in the formulation, these studies provide preliminary evidence for the efficacy of NAC in improving symptom severity in early-stage AD, and delaying the onset of decline in moderate to late-stage AD.

Group II metabotropic glutamate receptors (mGluR2/3) are located presynaptically on neurons in a large number of brain regions including the cortex, amygdala, hippocampus, and striatum [24], and play an important role in the regulation of the synaptic release of glutamate [25]. Stimulation of mGluR2/3 receptors by extracellular glutamate has an inhibitory effect on the synaptic release of glutamate [26]. Extracellular levels of glutamate are maintained primarily by means of the cystine–glutamate antiporter [27]. This Na+-independent antiporter is bound to plasma membranes and is found ubiquitously throughout the body, while being located predominantly on glial cells in the human brain [28]. Cystine is the disulfide derivative of cysteine, consisting of two oxidized cysteine residues. When extracellular levels of cystine are increased in the brain, the antiporters on glial cells exchange extracellular cystine for intracellular glutamate. This leads to the stimulation of mGluR2/3 receptors and inhibition of synaptic glutamate release. For this reason, cysteine prodrugs have the ability to reduce the synaptic release of glutamate, with important implications for the treatment of psychiatric disorders.

INHIBITION OF GLUTAMATE RELEASE IN OBSESSIVE COMPULSIVE DISORDER

A number of magnetic resonance spectroscopy (MRS) studies of obsessive compulsive disorder (OCD) have revealed abnormal glutamate transmission in brain regions associated with cortico-striatal-thalamo-cortical (CSTC) neurocircuitry. Glx, a composite measure of glutamate, glutamine, homocarnosine, and GABA, has been found to be elevated in the caudate in OCD patients and to normalize again following SSRI treatment [29–33]. This finding is consistent with the metabolic hyperactivity in CSTC circuits, which is a known hallmark of OCD [34]. In contrast, Glx levels have been found to be decreased in the anterior cingulate [35], a finding that parallels the inverse relationship between anterior cingulate and basal ganglia volume in OCD patients [36]. Further evidence of elevated glutamate levels associated with OCD comes from a study by Chakrabarty et al. [37], who reported increased levels of glutamate in the CSF of drug-naive OCD patients.

A number of studies have investigated the effects of glutamate-modulating drugs in the treatment of OCD spectrum disorders. In an open-label study using Riluzole, a pharmacological agent which reduces synaptic glutamate release, Pittenger et al. [38–39] reported a significant decrease in symptoms in 13 treatment-resistant OCD patients over a 12 week period. However, it has been found that not all anti-glutamatergic agents have been found to be effective, with topiramate (Topamax) being found to exacerbate OCD symptoms and Lamotrigine found to be ineffective [36]. There have also been mixed results found to date for the efficacy of memantine in the treatment of OCD [40]. This is most likely due to differences in the mechanism of action associated with each of these varied compounds.

Due to the effects of inhibiting synaptic glutamate release through glial cystine– glutamate exchange, NAC also been investigated as a possible treatment for OCD. In a case study of a 58 year-old woman with SRI-refractory OCD, Lafleur et al. [41] reported that NAC augmentation of fluvoxamine resulted in a marked reduction in OCD symptoms (Y-BOCS), and a clinically significant improvement in OCD symptoms. The NAC dose used in this study was titrated up from 1200 mg PO daily to 3000 mg daily over a 6 week period, and then maintained at this dosage level for a further 7 weeks. It is interesting to note that a reduction of 8 points on the Y-BOCS scale was noticed after only 1 week of treatment, which is indicative of rapid onset of treat-ment effects in comparison to conventional SSRI treatments for OCD, which may take several weeks for effects to become noticeable [42]. The possibility is also raised that there are acute effects associated with NAC use, whereby a patient with OCD may be able to use NAC on as-needed basis as an augmentation strategy for days when their symptoms are worse than usual. Two clinical trials are currently underway to test the efficacy of NAC in the treatment of OCD. Costa and colleagues from the University of Sao Paulo are conducting a 16-week intervention study using 3000mg/day NAC as an adjunctive treatment in OCD (NCT01555970) while Pittenger and colleagues from Yale University are conducting a 12-week study using 2400mg/day NAC for children aged 8–17 years (NCT01172275). It is hoped that these studies will provide important data as to the efficacy of NAC as treatment strategy for OCD.

A disorder related to OCD, which is classified as part of the OCD spectrum dis-orders is trichotillomania, characterized by repetitive hair pulling. Grant et al. [43] conducted a double-blind trial to assess the efficacy of NAC (1200–2400 mg/day) in 50 participants with trichotillomania over a 12 week period. Patients in the NAC treat-ment group were found to have significantly greater reductions in hair-pulling symptoms in comparison to placebo. Significant improvements were observed from 9 weeks of treatment onwards. Fifty-six percent of patients were found to be “much or very much improved” from the NAC treatment group in comparison to only 16% assigned to the placebo group. Another OCD spectrum disorder that NAC use has been investigated as a potential treatment strategy is compulsive nail-biting. Berk et al. [44] present three case studies where patients with a life-long history of compulsive nail-biting were found to benefit from NAC treatment. In the first case study, a 46 years old woman is reported to stop nail-biting altogether over a 7 months period using a dosage of 1000 mg NAC BID. In the second case study, a 44 years old woman is reported to stop nail biting after 4 months of treatment with NAC 1000 mg BID, and to have not recommenced on a 2 month follow-up. In the third case study, a 46 years-old patient was not reported to stop nail-biting all together, but noticed a reduction in this behavior after 28 weeks after starting NAC treatment. In addition to trichotillomania and nail-biting, NAC has also been reported to be effective in the reduction of skin-picking behavior [45].

A number of concerns will need to be addressed in assessing the suitability of NAC as a viable treatment option for OCD and related disorders, beyond a demonstration of efficacy. Considering the high degree of comorbidity of depression with OCD [46], it is necessary in further research to investigate the effects of NAC on mood. Although preclinical evidence to date is promising, it suggests that agonist acting on the mGluR2/3 receptors may dampen responses to stress and have a potential antidepressant effect [47–48], and the case study by Lafleur et al. [41] also reported a decrease in depression in their patient as measured by the HAM-D over the course of the trial. It may be important to monitor possible acute side effects of cognitive slowing that may result from over-regulation of glutamatergic tone with high-dose NAC use, as has been occasionally reported in relation to Riluzole [49].

Increased glutamate transmission in the nucleus accumbens has been found to be a mediator of drug-seeking behavior, while in the case of repeated use of drugs of abuse such as cocaine, a reduction in basal levels of extracellular glutamate in the nucleus accumbens are also observed [50,51]. Alterations in cystine–glutamate exchange and metabotropic glutamate receptor activity has also been found to regulate vesicular release of dopamine, another central neurotransmitter in reward-related behavior [26,52]. Due to its effects in inhibiting the synaptic release of glutamate in the CNS, NAC has been investigated for use in the treatment of substance abuse. Preclinical research by Baker et al. [52] revealed that systemic administration of NAC to cocaine-treated rats restored extracellular glutamate levels in the nucleus accumbens in vivo. Further, due to its effects on stimulating cystine–glutamate exchange, NAC was found to block cocaine-primed reinstatement of drug-taking behavior. In rats withdrawn from cocaine use, there is a change in the ability to create synaptic plasticity, which is related to alterations in prefrontal glutamatergic innervation of the nucleus accumbens core. Moussawi et al. [53] reported that the administration of NAC to cocaine-treated rats reversed the deficit in synaptic plasticity by indirect stimulation of mGlu2/3 and mGlu5 receptors, responsible for long-term potentiation and long-term depression, respectively.

In a pilot study investigating the effects of NAC on craving in 15 cocaine-dependent humans, LaRowe et al. [54] reported that 600 mg NAC administered at 12 h intervals over a 3 day period resulted in a significant reduction in the desire to use cocaine, interest in cocaine and cue viewing time, in the presence of cocaine-related cues. An open-label dose-ranging study of NAC in the treatment of cocaine dependence in humans was conducted by Mardikian et al. [55]. Twenty-three treat-ment-seeking cocaine-dependent patients were assigned to either NAC 1200, 2400, or 3600 mg/day over a 4 week trial. Sixteen of the patients completed the trial, and the majority of these either stopped using cocaine or significantly reduced their intake by the end of the trial. The higher doses of 2400 and 3600 mg/day were found to be more effective in treating cocaine-dependence, with higher retention rates in comparison to the lower dose of 1200 mg/day.

In human research using other drugs of abuse, similar results have been reported. In an open-label study investigating the use of NAC in cannabis addiction, Gray et al. [56] reported that 1200 mg NAC twice daily resulted in significant reductions in marijuana craving amongst 24 cannabis-dependent participants, as well as a trend-level reduction in marijuana usage, over a 4 week period. Knackstedt et al. [57] conducted a study to investigate the effect of nicotine on cystine–glutamate exchange in the nucleus accumbens and the efficacy of NAC in the treatment of nicotine addiction, using both animal and human data. Over a 21 day period, rats self-administered nicotine intravenously and 12 h following the last nicotine dose the brains were removed and immunoblotting was conducted in order to investigate changes in the catalytic subunit of the cystine–glutamate exchanger (xCT) or the glial glutamate transporter (GLT-1) in the nucleus accumbens, the ventral tegmental area (VTA), the amygdala, and the PFC. Decreased expression of the xCT was observed in the nucleus accumbens and the VTA, and decreased GLT-1 expression was observed in the nucleus accumbens. In the second part of the study, 29 nicotine-dependent human subjects were administered 2400 mg NAC/daily versus placebo for 4 weeks in a double-blind design. Smokers treated with NAC were found to report a greater reduction in the number of cigarettes smoked over the 4 week period in comparison to placebo, with a significant time × treatment group interaction when controlling for alcohol consumption.

Preclinical studies have demonstrated that levels of glutamate in the nucleus accumbens mediate reward-seeking behaviors in general [58], not only addictive behaviors related to pharmacological agents. A pilot study by Grant et al. [59] investigated the efficacy of NAC in the treatment of pathological gambling. Twenty-seven pathological gamblers were administered NAC over an 8 week period in an open-label design, start-ing with an initial dose of 600 mg/day that was titrated up over the first 4 weeks until a noticeable clinical improvement was seen, with a maximum possible dose being 1800 mg/day. The Yale-Brown obsessive compulsive scale modified for pathological gambling (PG-YBOCS) was used as the primary endpoint. PG-YBOCS scores were found to be significantly decreased by the end of the 8 weeks, with a mean effective NAC dose of 1476.9 ± 311.13 mg/day. Sixteen participants were classified as responders, defined by a 30% or greater reduction in PG-YBOCS score. Of these, 13 participants entered a double-blind follow-up phase, where they were randomized to either continue receiving their maximum dose from the open-label phase versus placebo over a 6 week period. At the end of the double-blind phase, 83.3% of the NAC group still met responder criteria in comparison to only 28.6% of those assigned to placebo. Although the first of its kind, this well-designed pilot study provides preliminary data in support of the efficacy of NAC in the treatment of pathological gambling.

A longer-term study by Bernardo et al. [60] investigating the effect of 2 g/day NAC on the use of alcohol, tobacco, and caffeine use in patients with bipolar disorder failed to find efficacy for NAC. Seventy-five participants were randomized to NAC or placebo over a 6 month period, with no significant changes in substance use observed over the length of the trial, with the exception of reduced caffeine intake in the NAC group at week 2. However, it is important to note that patients were selected for the study on the basis of clinical criteria for bipolar disorder, rather than a primary substance abuse disorder. For this reason, there were low rates of substance use in the cohort, which detracted from the statistical power necessary to determine a treatment effect.

CSF levels of GSH have been found to be decreased by 27% in drug-naive schizophrenia patients, while MRS has revealed that levels in the medial PFC are reduced by as much as 52% [61]. Decreased levels of GSH have also been reported in the caudate region in schizophrenia patients, as revealed by post-mortem assay [62]. There is evidence to suggest that decreased levels of GSH in schizophrenia are due to genetic polymorphisms in the genes responsible for GSH synthesis [63,64]. Due to the efficacy of NAC in boosting GSH levels in the CNS, it has been investigated for possible clinical benefits in the treatment of schizophrenia. Berk et al. [65] administered NAC 2000 mg/day versus placebo over a 6 month period to 140 patients with chronic schizophrenia, as augmentation to their regular antipsychotic medication. Patients receiving NAC were found to have a significant reduction in negative symptoms of schizophrenia as measured by the positive and negative symptoms scale (PNSS) as well as a reduction in clinical global impression of symptom severity (CGI-S) and CGI-improvement. These findings are corroborated by the research of Lavoie et al. [66], which has demonstrated that chronic NAC use at 2000 mg/day over 60 days improves mismatch negativity, a measure of NMDA receptor function, in schizophrenia patients. While the reason why restoring GSH levels and reducing oxidative stress in the brain brings about a clinical improvement in the negative symptoms of schizophrenia remains to be elucidated, these findings provide encouraging preliminary evidence for the efficacy of NAC as an augmentation strategy in treating this disorder.

Alterations in GSH metabolism have also been described as a feature of bipolar disorder as well as schizophrenia [67–69]. By applying the same rationale to bipolar disorder, Berk et al. [70] investigated whether boosting GSH levels through NAC supplementation would improve depressive symptoms in this disorder. Using a randomized controlled study design 75 individuals with bipolar disorder were administered NAC 2000 mg/day versus placebo over a 6 month period. NAC treatment was found to be associated with a significant improvement on the Montgomery Asberg depression rating scale (MASRS) after 20 weeks. The authors hypothesized that the clinical improvement could be attributed to the restoration of oxidative imbalances that are perturbed in bipolar disorder.

Oral doses of NAC up to 8000 mg/day have not been known to cause clinically significant adverse reactions [10], and in a review of over 46 placebo-controlled tri-als, with NAC administered orally to a total of 4000 people, no significant adverse effects from NAC treatment were observed [4]. In relation to high oral doses of NAC (around 10,000 mg) typically used in cases of acetaminophen overdose, a review by Miller and Rumack [71] reported that mild symptoms such as headache, lethargy, fever, or skin rash occur in around 1%–5% of patients, while more moderate symptoms such as increased blood pressure, chest pain, hypertension, rectal bleeding, and respiratory distress occur in less than 1% of patients. One potential cause for concern over NAC supplementation was raised in a study by Palmer et al. [72] where rats receiving high-dose NAC in vivo for 3 weeks developed pulmonary arte-rial hypertension (PAH). The authors linked the finding of PAH to the conversion of NAC to S-nitroso-N-acetylcysteine (SNOAC) and a resultant hypoxia-mimetic effect. However, it is important to note that the rats were continuously exposed to a dose per weight roughly 40 times higher than the dose typically used in human studies. Good manufacturing practice (GMP) is important for NAC to ensure minimal oxidization to its dimeric form (di-NAC). Di-NAC is pharmacologically active at very low concentrations, and has immunological effects opposite to that of NAC [73]. For this rea-son it is important that any NAC obtained for chronic usage is from a trusted source.

NAC is a substance with the potential to treat a diverse range of neuropathologies (see Table below for a summary of clinical research). In whole NAC is well tolerated, with a low incidence of adverse events in the dose ranges typically required for clinical effects. As a highly effective cysteine prodrug, NAC can both significantly boost endogenous GSH production and influence the synaptic release of glutamate due to its effects on cystine–glutamate exchange. For these reasons, NAC can be used as a means of ameliorating symptoms in wide range of disorders of the CNS including neurodegenerative disorders as well as obsessive-compulsive spectrum disorders, substance abuse disorders, behavioral addictions, schizophrenia, and bipolar disorder. Further large-scale trials of NAC are warranted in order to better establish clinically effective dosage ranges and treatment schedules for these varied neurodegenerative and neuropsychiatric conditions.

AD, Alzheimer’s disease; CGI, clinical global impression; DRS, dementia rating scale; MADRS, Montgomery Asberg depression rating scale; OCD, obsessive compulsive disorder; PANSS, positive and negative symptoms scale; PG-YBOCS, Yale-Brown obsessive compulsive scale modified for pathological gambling; RCT, double-blind randomized placebo-controlled trial; Y-BOCS, Yale-Brown obsessive compulsive scale.